Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ultragenyx Pharmaceutical's operating cash flow for the twelve months ending Jun 30, 2026 was -$485.00M. For fiscal 2025 it was -$466.00M. The highest annual figure on record is -$12.50M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$466.00M | – |
| FY2024 | Dec 31, 2024 | -$414.00M | – |
| FY2023 | Dec 31, 2023 | -$475.00M | – |
| FY2022 | Dec 31, 2022 | -$380.47M | – |
| FY2021 | Dec 31, 2021 | -$338.70M | – |
| FY2020 | Dec 31, 2020 | -$132.22M | – |
| FY2019 | Dec 31, 2019 | -$345.38M | – |
| FY2018 | Dec 31, 2018 | -$290.57M | – |
| FY2017 | Dec 31, 2017 | -$253.84M | – |
| FY2016 | Dec 31, 2016 | -$160.98M | – |
| FY2015 | Dec 31, 2015 | -$105.98M | – |
| FY2014 | Dec 31, 2014 | -$44.63M | – |
| FY2013 | Dec 31, 2013 | -$31.20M | – |
| FY2012 | Dec 31, 2012 | -$12.50M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$97.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$197.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$99.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$91.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$109.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$166.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$79.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$67.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$76.96M | – |
| Q1 FY2024 | Mar 31, 2024 | -$190.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$84.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$117.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$116.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$156.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$90.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$95.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$77.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$117.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$54.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$59.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$65.36M | -174.8% |
| Q1 FY2021 | Mar 31, 2021 | -$159.35M | – |
| Q4 FY2020 | Dec 31, 2020 | -$62.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$61.97M | – |
| Q2 FY2020 | Jun 30, 2020 | $87.35M | – |
| Q1 FY2020 | Mar 31, 2020 | -$95.15M | – |
| Q4 FY2019 | Dec 31, 2019 | -$72.04M | – |
| Q3 FY2019 | Sep 30, 2019 | -$88.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$89.06M | – |
| Q1 FY2019 | Mar 31, 2019 | -$95.78M | – |
| Q4 FY2018 | Dec 31, 2018 | -$55.85M | – |
| Q3 FY2018 | Sep 30, 2018 | -$69.16M | – |
| Q2 FY2018 | Jun 30, 2018 | -$76.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$89.48M | – |
| Q4 FY2017 | Dec 31, 2017 | -$81.82M | – |
| Q3 FY2017 | Sep 30, 2017 | -$61.99M | – |
| Q2 FY2017 | Jun 30, 2017 | -$48.82M | – |
| Q1 FY2017 | Mar 31, 2017 | -$61.21M | – |
| Q4 FY2016 | Dec 31, 2016 | -$47.68M | – |
| Q3 FY2016 | Sep 30, 2016 | -$28.75M | – |
See a number that looks wrong?